Compare Invesco Preferred ETF (PGX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Preferred ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Invesco Preferred ETF trades at $9.93 (market cap $3.58B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Preferred ETF for 96 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PGX | TVTX | |
|---|---|---|
Market Cap | $3.58B | $4.88B |
Volume | 10,976,352 | 1,668,577 |
52-Week High | $11.61 | $67.52 |
52-Week Low | $9.95 | $26.79 |
Typical Hold Time | 96 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGX trades at $9.98 with a modest 0.3% daily gain, though technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The stock faces significant resistance at $10, which also serves as multiple support levels. Recent corporate actions include scheduled dividends of $0.06 per share for H2-2026, providing income potential for shareholders.
The outlook remains cautious given the bearish technical setup and lack of available fundamental data. While dividend payments offer some investor appeal, the absence of key valuation metrics and financial ratios creates uncertainty about the company's underlying business performance and competitive positioning.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
